Biohaven Pharmaceutical has enrolled the first patient in a Phase ll/lll clinical trial to examine the efficacy and safety of trigriluzole (BHV-4157) for the treatment of patients with mild-to-moderate Alzheimer’s disease (AD).

The randomised, double-blind, placebo-controlled trial is being carried out in partnership with Alzheimer’s Disease Cooperative Study (ADCS) at various sites across the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Around 292 AD patients with mini-mental state examination scores of 14-24 at screening are expected to be enrolled in the trial.

In addition, patients who are on stable doses of the US Food and Drug Administration (FDA) approved AD medications, including acetylcholinesterase inhibitors (AchEI) and/or memantine, for at least three months prior to screening and who are willing to remain on the same regimen during the course of the trial can take part.

“Biohaven is committed to efficiently developing novel therapies for severe neurological diseases so this is an important clinical milestone for the company.”

The patients are set to be randomised in a 1:1 ratio to receive 280mg of trigriluzole or placebo, taken orally at bedtime, for a period of 48 weeks.

Biohaven Pharmaceutical executive director Irfan Qureshi said: “Biohaven is committed to efficiently developing novel therapies for severe neurological diseases so this is an important clinical milestone for the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Based on compelling preclinical research, trigriluzole represents a promising therapeutic option for patients and families suffering from mild-to-moderate Alzheimer’s disease and we look forward to collaborating with the ADCS.”

AD, a progressive, fatal neurodegenerative dementia, is estimated to account for 60% to 80% of the dementia cases.

No curable treatment is currently available for AD. However, FDA has approved some medications for symptomatic treatment of the disease.